A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis

Published on Apr 1, 2017in Arthritis & Rheumatism9.002
· DOI :10.1002/art.40044
Carol A. Langford40
Estimated H-index: 40
(Cleveland Clinic),
David Cuthbertson35
Estimated H-index: 35
(USF: University of South Florida)
+ 42 AuthorsJennifer Harris1
Estimated H-index: 1
Objective To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). Methods In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double-blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse-free survival rate). Results Forty-nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse-free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.
  • References (55)
  • Citations (109)
📖 Papers frequently viewed together
188 Citations
207 Citations
319 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Peter M. Villiger (University of Bern)H-Index: 44
#2Sabine Adler (University of Bern)H-Index: 10
Last. Stephan Reichenbach Oberarzt (University of Bern)H-Index: 36
view all 9 authors...
188 CitationsSource
#1Ritu Chakravarti (Cleveland Clinic)H-Index: 13
#2Karishma Gupta (Cleveland Clinic)H-Index: 7
Last. Gary S. Hoffman (Cleveland Clinic)H-Index: 61
view all 14 authors...
Large vessel vasculitis (LVV) is characterized by immune-mediated injury of predominantly large vessels. Histopathologic features include mononuclear cell infiltration of the vessel wall that often includes granuloma formation. Within this group of diseases, Takayasu arteritis (TAK) affects younger individuals (younger than 50 years; mean age ~26 years at onset), whereas giant cell arteritis (GCA) is unique to older patients (older than 50 years; mean age ~74 years at onset) (1). Both predominan...
12 CitationsSource
#1Tanaz A. Kermani (Mayo Clinic)H-Index: 18
#2Kenneth J. Warrington (Mayo Clinic)H-Index: 33
Last. Steven R. Ytterberg (Johns Hopkins University)H-Index: 40
view all 14 authors...
Objective. To evaluate the frequency, timing, and clinical features of relapses in giant cell arteritis (GCA). Methods. Patients with GCA enrolled in a prospective, multicenter, longitudinal study were included in the analysis. Relapse was defined as either new disease activity after a period of remission or worsening disease activity. Results. The study included 128 subjects: 102 women (80%) and 26 men (20%). Mean ± SD age at diagnosis of GCA was 69.9 ± 8.6 years. Mean followup for the cohort w...
47 CitationsSource
#1Raphaèle Seror (University of Paris-Sud)H-Index: 31
#2Gabriel Baron (Hotel Dieu Hospital)H-Index: 4
Last. Xavier Mariette (University of Paris-Sud)H-Index: 81
view all 11 authors...
116 CitationsSource
#1Michael Schiff (CU: University of Colorado Boulder)H-Index: 26
#2Michael E. Weinblatt (Brigham and Women's Hospital)H-Index: 78
Last. Roy Fleischmann (UTSW: University of Texas Southwestern Medical Center)H-Index: 60
view all 8 authors...
Objectives To compare over 2 years the safety, efficacy and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients with rheumatoid arthritis (RA). Methods AMPLE is a phase IIIb, 2-year, randomised, investigator-blinded study with a 1-year primary endpoint. Biologic-naive patients with active RA and an inadequate response to MTX were randomised to 125 mg abatacept weekly or 40 mg adalimumab bi-weekly, both with a stable dose of MTX. ...
155 CitationsSource
#1Sebastian UnizonyH-Index: 14
#2Bhaskar DasguptaH-Index: 35
Last. John H. Stone (Partners HealthCare)H-Index: 70
view all 9 authors...
Overview. The GiACTA trial is a multicenter, randomized, double-blind, and placebo-controlled study designed to test the ability of tocilizumab (TCZ), an interleukin (IL)-6 receptor antagonist, to maintain disease remission in patients with giant cell arteritis (GCA). Design. Approximately 100 centers will enroll 250 patients with active disease. The trial consists of a 52-week blinded treatment phase followed by 104 weeks of open-label extension. Patients will be randomized into one of four gro...
68 CitationsSource
#1Sebastian Unizony (Harvard University)H-Index: 14
#2L. Arias-Urdaneta (Harvard University)H-Index: 1
Last. John H. Stone (Harvard University)H-Index: 70
view all 8 authors...
Objective The interleukin-6 pathway is up-regulated in giant cell arteritis (GCA), Takayasu arteritis (TA), and polymyalgia rheumatica (PMR). We retrospectively assessed the outcomes of 10 patients with relapsing/refractory GCA, TA, or PMR treated with tocilizumab (TCZ). Methods Patients with GCA (n = 7), TA (n = 2), and PMR (n = 1) received TCZ. Seven subjects had failed at least 1 second-line agent. The outcomes evaluated were symptoms of disease activity, inflammatory markers, ability to tape...
184 CitationsSource
#1Peter C. Grayson (BU: Boston University)H-Index: 16
#2Kathleen Maksimowicz-McKinnon (Cleveland Clinic)H-Index: 20
Last. Peter A. Merkel (BU: Boston University)H-Index: 67
view all 14 authors...
Objectives To compare patterns of arteriographic lesions of the aorta and primary branches in patients with Takayasu9s arteritis (TAK) and giant cell arteritis (GCA). Methods Patients were selected from two North American cohorts of TAK and GCA. The frequency of arteriographic lesions was calculated for 15 large arteries. Cluster analysis was used to derive patterns of arterial disease in TAK versus GCA and in patients categorised by age at disease onset. Using latent class analysis, computer de...
143 CitationsSource
#1Jean Schmidt (French Institute of Health and Medical Research)H-Index: 7
#2Tanaz A. Kermani (Mayo Clinic)H-Index: 18
Last. Kenneth J. Warrington (Mayo Clinic)H-Index: 33
view all 6 authors...
Objective To report a single-center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA). Methods We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria. Results We included 20 patients (19 women, 17 white) with ...
67 CitationsSource
#1Haner Direskeneli (Marmara University)H-Index: 39
#2Sibel Zehra Aydin (Marmara University)H-Index: 29
Last. Peter A. Merkel (BU: Boston University)H-Index: 67
view all 12 authors...
Giant cell (GCA) and Takayasu’s arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap be...
61 CitationsSource
Cited By109
#1Emma Leacy (Trinity College, Dublin)
#2Gareth Brady (Trinity College, Dublin)H-Index: 11
Last. Mark A. Little (Trinity College, Dublin)H-Index: 31
view all 3 authors...
ANCA-associated vasculitis (AAV) is a severe systemic autoimmune disease. A key feature of AAV is the presence of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) directed against myeloperoxidase (MPO) or proteinase-3 (PR3). ANCA are key to the pathogenesis of AAV, where they activate innate immune cells to drive inflammation. Pre-activation or 'priming' of immune cells appears to be important for complete cellular activation in AAV. The burgeoning field of immunometabolism has illuminated the gove...
#1Zachary S. Wallace (Harvard University)H-Index: 18
#2Eli M. Miloslavsky (Harvard University)H-Index: 11
ABSTRACT Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a small to medium vessel vasculitis associated with excess morbidity and mortality. This review explores how management of AAV has evolved over the past two decades with pivotal randomized controlled trials shaping the management of induction and maintenance of remission. Contemporary AAV care is characterized by approaches that minimize the cumulative exposure to cyclophosphamide and glucocorticoids, increasingl...
1 CitationsSource
#1Lena Horvath (University of Tübingen)
#2Bernhard Hellmich (University of Tübingen)H-Index: 35
Patienten mit unbehandelter aktiver Riesenzellarteriitis sind durch das Risiko eines permanenten Visusverlusts akut gefahrdet, sodass umgehend eine Therapie mit Glukokortikoiden in einer Initialdosis von 40–60 mg Prednisolonaquivalent pro Tag begonnen werden sollte. Sobald eine Remission eingetreten ist, sollte die Prednisolon-Dosis innerhalb von 2 bis 3 Monaten auf 15–20 mg und danach innerhalb 1 Jahres auf ≤5 mg pro Tag reduziert werden. Bei Patienten mit erhohtem Risiko fur oder bereits beste...
#1Sarah L. Mackie (University of Leeds)H-Index: 19
#2Christian Dejaco (University of Graz)H-Index: 27
Last. Alexandre Wagner Silva de Souza (UNIFESP: Federal University of São Paulo)H-Index: 13
view all 36 authors...
#1Berit Dalsgaard Nielsen (Aarhus University Hospital)
#1Nielsen BdH-Index: 4
Last. Lars C. GormsenH-Index: 26
view all 2 authors...
18F-Fluorodeoxyglucose (FDG) PET/computed tomography (CT) is a highly accurate diagnostic tool for large vessel vasculitis (LVV) and is one of the recommended imaging modalities for confirmation of the diagnosis. This article focuses on the role of FDG-PET/CT in LVV diagnosis and disease monitoring, mainly focusing on giant cell arteritis; in particular, the diagnostic accuracy, diagnostic criteria, the potential pitfalls in the interpretation of large vessel FDG uptake, and the clinical indicat...
#1Xiaomeng Cui (Fudan University)H-Index: 2
#2Xiaomin Dai (Fudan University)H-Index: 4
Last. Lindi Jiang (Fudan University)H-Index: 6
view all 25 authors...
Abstract Objective To evaluate the efficacy and safety of leflunomide (LEF) as induction treatment in a series of Takayasu arteritis (TA) patients based on a Chinese cohort. Method Fifty-six patients from the East China TA cohort treated with LEF for at least 3 months were enrolled in this study, including the naive LEF treatment patients (n = 41) and the cyclophosphamide (CYC)- resistant LEF treatment patients (n = 15). Data in clinical features, NIH score and angiography were collected. Respon...
#1Kaitlin A. Quinn (NIH: National Institutes of Health)H-Index: 1
#2Joel Rosenblum (NIH: National Institutes of Health)H-Index: 2
Last. Peter C. Grayson (NIH: National Institutes of Health)H-Index: 16
view all 6 authors...
Abstract Objectives To determine the impact of imaging acquisition time on interpretation of disease activity on 18F-fluorodeoxyglucose positron emission tomography (PET) in large-vessel vasculitis (LVV) and assess the relationship between clinical features and image acquisition time. Methods Patients with giant cell arteritis (GCA) and Takayasu's arteritis (TAK) were recruited into a prospective, observational cohort. After a single injection of FDG, all patients underwent two sequential PET sc...
1 CitationsSource
Objective To compare the presence of head, neck and upper extremity symptoms in patients with Takayasu’s (TAK) and giant cell arteritis (GCA) and their association with vascular inflammation assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) or arterial damage assessed by magnetic resonance angiography (MRA). Methods Patients with TAK and GCA underwent clinical and imaging assessments within 24 hours, blinded to each other. Vascular inflammation was defined as arterial FDG...
1 CitationsSource